The potential role of appetite in predicting weight changes during treatment with olanzapine by Case, Michael et al.
RESEARCH ARTICLE Open Access
The potential role of appetite in predicting
weight changes during treatment with
olanzapine
Michael Case1*, Tamas Treuer2, Jamie Karagianis3, Vicki Poole Hoffmann1
Abstract
Background: Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It
has been suggested that weight changes in patients treated with olanzapine may be associated with increased
appetite.
Methods: Data were used from adult patients for whom both appetite and weight data were available from 4
prospective, 12- to 24-week clinical trials. Patients’ appetites were assessed with Eating Behavior Assessment (EBA,
Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI,
Study 3), and Eating Attitude Scale (EAS, Study 4).
Results: In Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating
an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI),
patients who reported overall score increases on appetite scales did not experience greater weight changes than
patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with
overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional
information was gained by adding early appetite change to early weight change in correlation to overall weight
change.
Conclusions: Early weight changes may be a more useful predictor for long-term weight changes than early score
changes on appetite assessment scales.
Clinical Trials Registration: This report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were
registered at http://clinicaltrials.gov/ct2/home, under NCT00190749, NCT00303602, and NCT00401973, respectively.
Study 4 predates the registration requirements for observational studies that are not classified as category 1
observational studies.
Background
Treatment with atypical antipsychotics has been tem-
porally associated with weight gain. Hypotheses about
the potential mechanism have included direct effects of
the known receptor affinities of each compound [1,2],
effects on gastric and intestinal hormones [3], direct or
indirect effects on the feeding and satiety centers in
the brain [4], disturbance of the hypothalamus-pitui-
tary-adrenal (HPA) axis [5], direct effect on insulin
sensitivity [6], decrease in physical activity, and
decrease in metabolic rate [7].
The extent of weight change and changes in metabolic
parameters during treatment with antipsychotics varies
between drugs. These variations may be due to differences
in receptor pharmacology [8]. Kroeze et al. demonstrated
that affinity to the histamine H1 receptor predicts weight
gain associated with typical and atypical antipsychotics [9].
Olanzapine and clozapine both have high affinities for the
5-HT2C and the histamine H1 receptors, while antagon-
ism of peripheral M3 muscarinic receptor and effects on
central 5-HT2C may potentially be related to treatment-
emergent diabetes observed independent of obesity.
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While potential mechanisms for weight gain have
been widely studied, the role of changes in appetite
remains poorly understood. It is well known that
executive functions are necessary to successfully man-
age eating behavior, and their impairment and dis-
turbed weight regulation are often observed in patients
with schizophrenia treated with antipsychotics. A
recent pilot study showed that a delay of gratification
and executive performance in individuals with schizo-
phrenia may play a putative role for eating behavior
and body weight regulation [10]. Additionally, increas-
ing evidence suggests that general obesity is linked to
adverse neurocognitive outcomes. Altered cognitive
functions can independently affect the control of appe-
tite [11]. Treatment with both clozapine and olanza-
pine have been temporally associated with food craving
and binge eating [12,13].
Previous studies have observed that patients treated
with atypical antipsychotics are more reactive to exter-
nal eating cues as measured by the Three Factors Eating
Behavior Questionnaire and the Dutch Eating Behavior
Questionnaire [14]. Based on the observation of an asso-
ciation between weight gain and lack of cognitive
restraint in the presence of increased appetite, it has
been suggested that psychoeducational counseling in
conjunction with adjunctive pharmacotherapeutic agents
might limit weight gain during antipsychotic drug
therapy [15].
An understanding of the role of appetite changes in
weight gain during antipsychotic treatment would be
helpful to clinicians and patients, some of whom report
substantially increased appetite starting after their first
dose of an antipsychotic.
Changes in appetite might serve as early warning signs
of risk of weight gain as well as inform treatment deci-
sions. If specific changes in appetite can be expected,
patients can be informed in advance and may be better
able to manage them. Here we test the hypothesis that
changes in appetite might be indicative of a patient’s
weight gain during treatment with olanzapine.
Methods
Presented are secondary analyses examining potential
associations between changes in appetite and weight
changes during treatment with olanzapine. The primary
study objectives have been reported elsewhere [16-19].
The study protocols were reviewed and approved by
individual institutional review boards prior to enrolling
any patients, and the analyses presented here are consis-
tent with the original ethics approvals. The studies were
consistent with Good Clinical Practices and all applic-
able regulatory requirements. All participants provided
written informed consent before receiving study therapy
or undergoing study procedures.
Study design
Included in the analyses were patients from 4 prospec-
tive, phase IV clinical trials examining the efficacy and
safety of olanzapine in adult (18 to 65 years old in
Studies 1, 2, and 3, ≥18 years old in Study 4) male and
female patients diagnosed with schizophrenia, schizoaf-
fective disorder, related psychosis, or bipolar disorder.
In Study 1, patients received double-blind oral olanza-
pine 5-20 mg once daily (QD) for 12 weeks [16]. In
Study 2, patients received double-blind oral olanzapine
5-20 mg QD for 16 weeks [18]. In Study 3, patients
received open-label oral olanzapine 5-20 mg QD for
22 weeks [19]. Study 4 was an observational study in
which patients received oral olanzapine at doses deter-
mined by the investigator as appropriate for the indivi-
dual patient for 6 months (Table 1) [17]. Detailed
inclusion and exclusion criteria can be found in the
primary study reports [16-19].
Clinical assessment of appetite
Across all 4 studies, appetite was assessed with 5 differ-
ent scales: Eating Behavior Assessment (EBA, a Lilly-
developed scale, assessing appetite and eating behavior
with 9 standardized questions, grading responses on a
scale from 0 to 4, where 0 = not at all and 4 = extre-
mely; not validated; Study 1); Platypus Appetite Rating
Scale (PARS, a Lilly-developed visual analog scale; not
validated; Study 2); Eating Inventory (EI, Study 3) [20];
Food Craving Inventory (FCI, Study 3) [21]; and Eating
Attitude Scale (EAS, a Lilly-developed scale, assessing
appetite and eating behavior during the past 4 weeks
with 10 standardized categories; not validated; Study 4)
(Table 1).
Statistical analysis
For each study, only patients for whom weight and
appetite data at baseline, at 2 weeks (Study 4, 4 weeks),
and at ≥1 later visit were available, were included in our
analyses. Patients were assigned to distinct groups based
on their overall and 2-week (Study 4, 4-week) appetite
scale item scores and total scores. Score increase was
defined as: positive value on EBA, >+5 units on PARS,
>+1 unit on EI, >+1 unit on FCI, or > 0 units on EAS.
No change in score was defined as: 0 units on EBA, ≥-5
to ≤+5 units on PARS, ≥-1 to ≤ +1 units on EI, ≥-1 to
≤+1 units on FCI, or 0 units on EAS. Score decrease
was defined as: negative value on EBA, <-5 units on
PARS, <-1 unit on EI, <-1 unit on FCI, or <0 units on
EAS. For each group, mean overall weight change and
mean appetite scale score changes were determined
using observed case analyses. Additionally, to test the
hypothesis of a linear trend between appetite and
weight changes (i.e. greater increases in appetite are
associated with greater increases in weight), pair-wise
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comparisons of mean weight changes in the “decrease”
versus “no change” and the “no change” versus
“increase” appetite groups were conducted. If both of
these tests were significant and the magnitudes of the
changes followed the hypothesized pattern, a linear
trend would be suggested.
Additionally, several Pearson correlation coefficients
were assessed and tested for statistical significance: a)
between weight changes from baseline to endpoint and
score changes on appetite scales from baseline to
2 weeks (Study 4, 4 weeks); b) between weight changes
from baseline to endpoint and changes on appetite
scales from baseline to endpoint; c) between baseline to
endpoint weight changes and 2-week (Study 4, 4-week)
weight changes; and d) between overall weight change
and 2-week appetite scale changes, adjusted by 2-week
weight change (the correlation of appetite changes on
the residuals from the regression of endpoint weight
changes on 2-week weight changes).
Results
Patients
Baseline demographic data for all patients included in
our analyses are presented in Table 2. The distribution
of patient ethnicities was different across all 4 studies.
Study 1 included a majority of African American
patients, while Studies 2 and 3 included mainly white
patients, and the majority of patients in Study 4 self-
identified as East and Southeast Asians.
Weight changes
In all 4 studies, patients experienced statistically signifi-
cant (p <.05) mean weight increases from baseline to
endpoint (Study 1: 86.3 kg at baseline, 89.6 kg at end-
point; Study 2: 81.2 kg at baseline, 84.1 kg at endpoint;
Study 3: 85.4 kg at baseline, 90.8 kg at endpoint; Study
4: 64.1 kg at baseline, 68.3 kg at endpoint).
Appetite changes
An increase in patients’ appetite from baseline to endpoint
was observed in Study 1 (EBA item #1: 1.5 at baseline, 1.7
at endpoint, p = .21; EBA item #2: 1.6 at baseline, 1.6 at
endpoint, p = .72; EBA item #3: 1.1 at baseline, 1.2 at end-
point, p = .11; EBA item #4: 0.9 at baseline, 1.1 at end-
point, p = .22; EBA item #5: 2.5 at baseline, 2.5 at
endpoint, p = .35; EBA item #6: 0.9 at baseline, 1.1 at end-
point, p = .42; EBA item #7: 0.9 at baseline, 1.0 at end-
point, p = .32; EBA item #8: 0.4 at baseline, 0.6 at
endpoint, p = .36; EBA item #9: 0.1 at baseline, 0.3 at end-
point, p = .12), while in Studies 2, 3, and 4, patients’ appe-
tites decreased in the course of the trials (Study 2 - PARS:
65.7 at baseline, 58.9 at endpoint, p = .04; Study 3 - EI
cognitive restraint: 7.6 at baseline, 11.3 at endpoint, p =
.09, EI disinhibition: 8.7 at baseline, 5.4 at endpoint, p =
.16, EI hunger: 7.9 at baseline, 4.8 at endpoint, p = .17, FCI
total: 65.4 at baseline, 61.5 at endpoint, p <.0001; Study 4 -
EAS 1: 1.6 at baseline, 1.4 at endpoint, p <.0001, EAS 2:
1.6 at baseline, 1.4 at endpoint, p <.0001, EAS 5: 2.3 at
baseline, 2.1 at endpoint, p <.0001, EAS 6: 1.3 at baseline,
1.1 at endpoint, p <.0001, EAS 7: 1.2 at baseline, 1.1 at
endpoint, p <.0001, EAS 8: 0.7 at baseline, 0.5 at endpoint,
p = .85, EAS 9: 0.6 at baseline, 0.5 at endpoint, p = .48).
Associations between appetite scale score changes and
weight changes
In Studies 1 (EBA) and 4 (EAS), score increases on single
appetite assessment scale items, both at 2 or 4 weeks and
at last measurement, indicating an increase in appetite,
occurred in patients who experienced the greatest overall
weight gains (Figures 1a+b, 2a+b). However, in Studies 2
(PARS) and 3 (EI, FCI), patients who reported score
increases on appetite scales items at 2 weeks and/or at last
measurement did not consistently experience greater
weight changes than patients reporting no score changes
or score decreases. The only individual appetite scale item
Table 1 Summary of Study Designs
Study 1 Study 2 Study 3 Study 4
Patient age (years) 18 to 65 18 to 65 18 to 65 ≥18
Study design Double-blind Double-blind Open-label Observational
Olanzapine dose (mg) 5 to 20 mg QD 5 to 20 mg QD 5 to 20 mg QD Determined by the
investigator
Adjunctive
pharmacotherpay
no no no or
Amantadine 100 mg BID or
Metformin 500 mg BID
no
Appetite assessment
scale
Eating Behavior
Assessment
Platypus Appetite Rating
Scale
Eating Inventory and Food Craving
Inventory
Eating Attitude Scale
Dietary counseling yes no yes no
Study length (weeks) 12 16 22 24
Abbreviations: BID = twice daily; QD = once daily.
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that was correlated with later weight increase was an
increase in the appetite for fatty fast food at 2 weeks in
patients in Study 3 who showed the greatest overall weight
change. Analysis of overall total score changes on appetite
scales for Studies 1, 2, and 3 (no total score available for
Study 4) showed that patients who experienced a decrease
in total scores in appetite assessment scales had the lowest
weight gains (≤1.6 kg).
Statistically significant differences in the pair-wise com-
parisons among patient groups with distinct appetite rat-
ing scale scores were observed in Studies 1 (Figures 1a
and 1b) and 4 (Figures 2a and 2b), where the “increase”
appetite group showed significantly greater weight
change than the “no change” appetite group on specific
EBA and EAS items. However, the “decrease” appetite
groups did not show significantly less weight change than
the “no change” appetite groups on these same items.
Correlation coefficients between appetite scale score
changes and weight changes
In all 4 studies, early weight changes (2-4 weeks) had
stronger correlations to overall weight changes than
both overall and early (2-4 weeks) changes on any appe-
tite scale examined (Table 3). Adjustment of early appe-
tite scale changes by early weight changes demonstrated
that early appetite scale assessments in conjunction with
early weight changes do not provide additional informa-
tion for predicting overall weight changes.
Discussion
Our analyses demonstrate an inconsistent association
between changes in appetite and weight change during
treatment with olanzapine; results varied depending on
study and appetite assessment scale used. Overall, early
weight changes may be a more useful predictor of long-
term weight changes compared with early score changes
on appetite assessment scales. To our knowledge, this is
the first study exploring a potential correlation between
changes in appetite and weight changes during treat-
ment with olanzapine.
Our observation that early weight changes correlate
strongly with long-term weight changes is in agreement
with earlier findings [22]. The absence of a consistent
correlation between changes in appetite and weight
Table 2 Baseline Demographics and Clinical Characteristics
Parameter Study 1 (N = 68) Study 2 (N = 65) Study 3 (N = 50) Study 4 (N = 622)
Age (years), mean (SD) 43.5 (9.5) 38.7 (12.2) 38.5 (12.0) 35.6 (12.2)
Male gender, n (%) 45 (66.2) 33 (50.8) 120 (60.3) 269 (43.2)
Ethnicity, n (%)
White 27 (39.7) 36 (55.4) 87 (43.7) 148 (23.8)
African American 34 (50.0) 4 (6.2) 16 (8.0) 0
East/Southeast Asian 1 (1.5) 1 (1.5) 39 (19.6) 369 (59.3)
Native American 0 0 0 0
Hispanic 4 (5.9) 23 (35.4) 52 (26.1) 83 (13.3)
West Asian 0 0 4 (2.0) 1 (0.2)
Other 2 (2.9) 1 (1.5) 0 0
Native American/First Nation 0 0 1 (0.5) 0
Missing 0 0 0 21 (3.4)
Weight (kg), mean (SD) 86.3 (16.8) 81.2 (17.0) 77.5 (16.6) 64.1 (12.5)
BMI, mean (SD) 28.7 (5.1) 28.3 (4.8) 27.1 (4.7) 23.2 (3.9)
Appetite, mean (SD) EBA Item #1: 1.5 (1.1)a PARS: 65.7 (19.2) EI-Cognitive Restraint: 7.6 (5.2)b EAS 1: 1.6 (1.2)c
EBA Item #2: 1.6 (1.1)a EI-Disinhibition: 8.7 (4.6)b EAS 2: 1.6 (1.1)c
EBA Item #3: 1.1 (1.2)a EI-Hunger: 7.9 (4.5)b EAS 5: 2.3 (1.2)d
EBA Item #4: 0.9 (1.1)a FCI Total: 65.4 (20.1) EAS 6: 1.3 (1.2)f
EBA Item #5: 2.5 (1.0)a EAS 7: 1.2 (1.2)f
EBA Item #6: 0.9 (1.2)a EAS 8: 0.7 (0.9)f
EBA Item #7: 0.9 (1.2)a EAS 9: 0.6 (0.9)f
EBA Item #8: 0.4 (0.9)a
EBA Item #9: 0.1 (0.3)a
Abbreviations: BMI = Body Mass Index; EAS = Eating Attitude Scale; EAS 1 = More hungry than usual; EAS 2 = Stronger appetite than usual; EAS 5 = Felt comfortably
full when meal was finished; EAS 6 = It took an excessive amount of food to feel full; EAS 7 = Thoughts were preoccupied with food; EAS 8 = Ate until
uncomfortably full; EAS 9 = Could not stop eating; EB = Eating Behavior Assessment; EI = Eating Inventory; FCI = Food Craving Inventory; kg = kilograms;
N = number of patients in study included in the current analyses; n = number of patients affected; PARS = Platypus Appetite Rating Scale; SD = standard deviation;
a n = 68; b only assessed in patients in the United States, n = 17; c n = 606; d n = 602; e n = 604; f n = 605.
Case et al. BMC Psychiatry 2010, 10:72
http://www.biomedcentral.com/1471-244X/10/72
Page 4 of 9
changes was an unexpected finding, as one would expect
that changes in appetite will result in changes in eating
habits and consequently changes in weight. We cannot
exclude the possibility that the appetite assessment
scales might not have accurately measured appetite in
our patient population. However, weight increase during
treatment with olanzapine might not be associated with
increased appetite. In experiments with female rats,
hyperphagia and sedation were observed to occur con-
comitantly during exposure to olanzapine, two behaviors
that interact competitively without necessarily increasing
appetite [15,23]. However, earlier studies with sulpiride
showed that there is no weight gain in female rats in
the absence of hyperphagia [24]. Another reason for the
inconsistency of our observations might be the possibi-
lity that weight gain during treatment with olanzapine
may be associated with several biochemical mechanisms,
which might manifest in a variety of clinical conditions
accompanying weight gain [25].
The observed variations in associations between changes
on appetite assessment scales and weight changes might
also be due to inherent differences between the scales that
were utilized and differences among the study populations.
One such difference among study populations might be
the extent of clinical improvement during therapy. While
our analysis is limited by the lack of a subanalysis of clini-
cal improvement versus appetite, it has been observed pre-
viously that clinical improvement of psychotic symptoms
in patients with schizophrenia seems to coincide with
increased food intake [26]. Interestingly, EBA and EAS,
which showed within the examined assessment scales the
greatest similarities with one another with regard to items
included, were also most similar in their assessment
results. EBA and EAS were the only appetite scales for
Figure 1 Study 1 – A) Relationship of overall EBA item score changes and overall weight changes. B) Relationship of 2-week EBA item
score changes and overall weight changes. Abbreviations: EBA = Eating Behavior Assessment; kg = kilogram.
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which patients with a score increase indicating increased
appetite consistently showed the greatest overall weight
gains compared with patients with no score increase.
Additionally, score increases of several EBA and EAS
items that might indicate binge eating showed strong cor-
relations with weight gain.
All correlation analyses were repeated using a 7%
increase in weight (clinically significant weight gain) as
cutoff point. The results from those analyses were in
agreement with the presented data from analyses exam-
ining correlations between change in weight and change
in appetite assessment scale scores.
Our analyses were limited by the differences in study
design across the 4 studies that were utilized: differences
included study length, numbers and geographic locations
of participating sites (resulting in different patient ethni-
cities), previous antipsychotic exposure, timing of appe-
tite assessment, co-treatment of some patients in Study 3
with amantadine or metformin, and blinding procedures.
Additionally, in Studies 1 and 3 patients received dietary
counseling to control potential weight gain, while
patients did not receive dietary counseling in Studies 2
and 4. Interestingly, the strongest correlations between
change in appetite and change in weight were observed
in Study 1, which was also the shortest study included in
the current analyses and the only study in which
increased appetite was observed (12 weeks versus 16 to
24 weeks for Studies 2, 3, and 4). In Study 2, patients had
Figure 2 Study 4 –- A) Relationship of overall EAS item score changes and overall weight changes. B) Relationship of 4-week EAS item
score changes and overall weight changes. Abbreviations: EAS = Eating Assessment Scale; kg = kilogram.
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to have already gained at least 5 kg or 1 unit of body
mass index (BMI) before randomization; therefore, most
appetite increase probably occurred before the study
started, especially when considering that all patients had
been receiving olanzapine for 6 to 54 weeks before the 2-
week appetite assessment occurred. Consequently, com-
parisons between Study 2 and Studies 1, 3, and 4 have to
be approached very carefully. For all studies analyzed
here, it is possible that appetite assessments might not
have been administered early enough in the course of
treatment to capture meaningful changes; our earliest
measurements are at 2 weeks, but changes in appetite
might have occurred as early as Day 1 of treatment, and
by 2 weeks weight changes were as informative as appe-
tite changes. Additionally, the use of different appetite
assessment scales limits comparisons across studies and
most of the appetite scales used here have not been vali-
dated. Within each study, appetite assessment scales
Table 3 Weight Changes and Appetite Scale Score Changes
Overall Changea 2- or 4-Week Changeb 2- or 4-Week Change - Adjustedc
Study 1 - Eating Behavior Assessment
How hungry? .304* (n = 59) .058 (n = 59) -.050 (n = 59)
Appetite? .282* (n = 59) .157 (n = 59) .097 (n = 59)
Craved sweets? .444*** (n = 59) .336** (n = 59) .238 (n = 59)
Craved fatty? .356** (n = 59) .243 (n = 59) .229 (n = 59)
Felt full? -.062 (n = 59) .048 (n = 59) .039 (n = 59)
Ate excessive amount? .277* (n = 59) .240 (n = 59) .117 (n = 59)
Thinking of food? .427*** (n = 59) .164 (n = 59) .129 (n = 59)
Overeating? .482*** (n = 59) .345** (n = 59) .209 (n = 59)
Out of control eating? .493*** (n = 59) .299* (n = 59) .154 (n = 59)
Study 1 – Weight 1 (n = 59) .533*** (n = 59) N/A
Study 2 – Platypus Appetite Rating Scale .141 (n = 65) .090 (n = 63) .101 (n = 63)
Study 2 – Weight 1 (n = 63) .502*** (n = 63) N/A
Study 3 – Eating Inventoryd
Cognitive Restraint -.012 (n = 66) .044 (n = 66) .227 (n = 66)
Disinhibition .138 (n = 66) -.089 (n = 66) -.084 (n = 66)
Hunger -.046 (n = 66) -.196 (n = 66) -.139 (n = 66)
Study 3 – Food Craving Inventory
Carbohydrates -.063 (n = 188) -.046 (n = 186) -.061 (n = 186)
Fatty Fast Food .019 (n = 188) -.037 (n = 188) -.032 (n = 188)
High Fat .045 (n = 187) .001 (n = 186) -.029 (n = 186)
Sweets -.017 (n = 188) -.030 (n = 187) -.048 (n = 187)
Total .001 (n = 185) -.024 (n = 184) -.051 (n = 184)
Study 3 – Weight 1 (n = 189) .507*** (n = 189) N/A
Study 4 – Eating Attitude Scale
More hungry than usual .162*** (n = 611) .153*** (n = 605) .013 (n = 591)
Stronger appetite than usual .198*** (n = 611) .173*** (n = 605) .023 (n = 591)
Felt comfortably full when meal was finished -.018 (n = 609) -.025 (n = 600) -.041 (n = 591)
It took an excessive amount of food to feel full .212*** (n = 610) .119** (n = 603) -.029 (n = 591)
Thoughts were preoccupied with food .189*** (n = 609) .199*** (n = 604) .069 (n = 591)
Ate until uncomfortably full .105** (n = 610) .116** (n = 603) -.001 (n = 591)
Could not stop eating .019 (n = 610) .106** (n = 603) .027 (n = 591)
Study 4 – Weight 1 (n = 608) .561*** (n = 608) N/A
a Pearson Correlation Coefficients between overall weight change and overall appetite scale changes or overall weight change.
b Pearson Correlation Coefficients between overall weight change and 2-week appetite scale changes or 2-week weight change; Study 4: Pearson Correlation
Coefficients between overall weight change and 4-week appetite scale changes or 4-week weight change.
c partial Pearson Correlation Coefficients between overall weight change and 2-week appetite scale changes, adjusted by 2-week weight change (the correlation
of appetite changes on the residuals from the regression of endpoint weight changes on 2-week weight changes).
*p < .05; **p < .01; ***p < .001.
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were administered repeatedly to all patients, which might
have desensitized the scales and resulted in a loss of
accuracy. Also, the analyses were not adjusted for base-
line psychopathology in the different patient groups and
for dose of olanzapine. Finally, the cutoffs to define
patient groups that experienced appetite scale score
increases, no change, or decreases were based on clinical
experience, but without access to previous reports in the
literature to guide this decision. Future research is war-
ranted to further assess the validity of the chosen cutoffs.
Conclusion
In conclusion, no consistent correlation between
changes in appetite and weight changes could be
observed in our analysis. However, when it was present,
it was in the expected direction, and the trend was con-
sistently in the expected direction. Consequently, appe-
tite change should be considered in patient care, but
when regular weight monitoring is performed, appetite
does not add additional information predicting future
weight changes during treatment with olanzapine: early
weight change may be a more useful predictor for long-
term weight change. Patients who experience early
weight gain or are otherwise at risk for significant
weight gain during olanzapine treatment should receive
regular monitoring of weight and lifestyle educational
programs early in the course of illness and of treatment.
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